Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
DSIP evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
med high
Regulatory
not approved
WADA
none
FDA
unknown
Route
intravenous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
DSIP (Delta Sleep-Inducing Peptide) has uncertain biology and receptor targets, but human studies exist. IV infusions at 25 nmol/kg show reported sleep pressure effects. The evidence is older and mixed. Mechanistic certainty is low, and the contested biology increases the need for sourcing credibility.
Decision path
Where DSIP fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether DSIP belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Biology and receptor targets remain unclear; human studies exist but mechanistic certainty is low.
intravenous, subcutaneous
Human: slow IV infusion at 25 nmol/kg.
Sleep pressure effects in some human studies; outcomes inconsistent across trials.
Acute subjective effects reported after dosing; sleep architecture outcomes assessed same day/night.
No established label.
Limited modern safety data; moderate uncertainty.
Unknown; avoid polypharmacy recommendations.
Cost at a glance
Typical cycle cost
€8.02
Estimated monthly
€16.05
Protocol style
Acute / short run
Intermittent
Estimate confidence
High confidence
Assumes roughly 1.5 mg–4 mg per cycle, using 1 tracked affiliated listing.
Best treated as acute or short-run use instead of a classic cycle.
Known Interactions
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for DSIP.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.